Trial Profile
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Mirogabalin (Primary)
- Indications Postherpetic neuralgia
- Focus Registrational; Therapeutic Use
- Acronyms NEUCOURSE
- Sponsors Daiichi Sankyo Company
- 28 May 2021 Results of pooled analysis of two studies (NCT02318706; DS5565-A-J303 & NCT02318719; DS5565-A-J304) assessing mirogabalin safety and efficacy, published in the Clinical Therapeutics.
- 04 Sep 2020 Results (n=239) assessing long-term safety and efficacy of mirogabalin, published in the Medicine.
- 01 May 2019 Results assessing the efficacy and safety of mirogabalin in Post-herpetic Neuralgia Asian patients with published in the Pain